Occam Places Mark Strobeck on the Board of Windtree

Occam Places Mark Strobeck on the Board of Windtree

Windtree Therapeutics, Inc. (Nasdaq: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders has appointed Mark Strobeck, Ph.D. to its Board of Directors.

Mark comes to Windtree with more than 20 years of richly varied experience in operations, business development, capital raising, and M&A.  Currently, he serves as President and CEO, and Board Member of Rockwell Medical, a publicly held healthcare company that develops, manufactures, commercializes, and distributes a portfolio of products for dialysis providers worldwide.

Prior to joining Rockwell in 2022, Mark was a Managing Partner at Aquilo Partners, a life science investment banking firm specializing in M&A and strategic partnering transactions. Previous executive roles have found him at Zyla Lifesciences (acquired by Assertio Therapeutics), Corridor Pharmaceuticals (acquired by AstraZeneca), Topaz Pharmaceuticals (acquired by Sanofi Pasteur), and GSK.

Mark holds a Ph.D. in pharmacology and cell biophysics from the University of Cincinnati.

About Occam Global

Occam Global is an executive recruiting and leadership advisory firm with specialties across technological fields including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.